BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34386930)

  • 1. MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.
    Liu W; Liu R; Yuan R; Wang X
    Mol Biotechnol; 2021 Dec; 63(12):1268-1279. PubMed ID: 34386930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 3. miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway.
    Wan J; Ling X; Peng B; Ding G
    Oncol Rep; 2018 Jul; 40(1):272-282. PubMed ID: 29767245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
    Roshani Asl E; Rasmi Y; Baradaran B
    J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC.
    Xie WB; Liang LH; Wu KG; Wang LX; He X; Song C; Wang YQ; Li YH
    Cell Physiol Biochem; 2018; 46(2):654-663. PubMed ID: 29617683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a.
    Chen Y; Song W; Gao Y; Dong X; Ji X
    Tohoku J Exp Med; 2022 May; 257(1):33-43. PubMed ID: 35354691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells.
    Sp N; Kang DY; Lee JM; Jang KJ
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
    Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
    J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.
    Jiang K; Zou H
    Bioengineered; 2022 Jan; 13(1):917-929. PubMed ID: 34968160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis.
    Zhang N; Fan J; Deng Z
    Anticancer Drugs; 2022 Jun; 33(5):437-447. PubMed ID: 35324518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
    FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo.
    Li J; Zhong X; Zhao Y; Shen J; Xiao Z; Pilapong C
    Sci Rep; 2024 Jan; 14(1):2348. PubMed ID: 38287075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis.
    Li S; Mei Z; Hu HB; Zhang X
    J Cell Physiol; 2018 Sep; 233(9):6679-6688. PubMed ID: 29215698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S; Wang K; Huang X; Zhao Z; Zhao Z
    Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-125a regulates HAS1 and inhibits the proliferation, invasion and metastasis by targeting STAT3 in non-small cell lung cancer cells.
    Huang H; Huang J; Yao J; Li N; Yang Z
    J Cell Biochem; 2020 Jun; 121(5-6):3197-3207. PubMed ID: 31930562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-130a enhances the killing ability of natural killer cells against non-small cell lung cancer cells by targeting signal transducers and activators of transcription 3.
    Zhou X; Liu S; Liu J; Zhang Z; Mao X; Zhou H
    Biochem Biophys Res Commun; 2020 Mar; 523(2):481-486. PubMed ID: 31883616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-454 inhibits non‑small cell lung cancer cells growth and metastasis via targeting signal transducer and activator of transcription-3.
    Liu S; Ge X; Su L; Zhang A; Mou X
    Mol Med Rep; 2018 Mar; 17(3):3979-3986. PubMed ID: 29286124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NEDD4L suppresses PD-L1 expression and enhances anti-tumor immune response in A549 cells.
    Zhong B; Zheng J; Wen H; Liao X; Chen X; Rao Y; Yuan P
    Genes Genomics; 2022 Sep; 44(9):1071-1079. PubMed ID: 35353342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.